Urothelial Carcinoma Market Size

DelveInsight's "Urothelial Carcinoma- Market Insights, Epidemiology and Market Forecast-2028" report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of urothelial carcinoma in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of urothelial carcinoma from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017-2028


Urothelial Carcinoma - Disease Understanding and Treatment Algorithm

Urothelial carcinoma is the invasion of the basement membrane or lamina propria by neoplastic cells of urothelial origin. The WHO has substituted the old-term provisional cell carcinoma with urothelial carcinoma. Invasion is referred to as 'micro invasion' when the complexity of invasion is 2 mm or less. The majority of UC occurs in males and approximately has two- to threefold greater incidence as compared to females. The main causative agents of upper tract urothelial carcinoma and urinary bladder cancer include cigarette smoking and work-related exposure, while other factors are more specific to the carcinogenesis of upper tract urothelial carcinoma (i.e., Balkan endemic nephropathy).

The diagnostic workup of urothelial carcinoma requires diagnosis modalities used in BC include imaging (ultrasound, intravenous urography (IVU), computed tomography (CT), and magnetic resonance imaging (MRI)), cystoscopy, biopsy, immunocytology (uCyt+), BTA-TRAK, BTA-STAT analyses, and others. New molecular-based urinary tests are used for reducing or substituting, the endoscopy frequency in BC recurrence patients. The diagnosis requires careful interpretation of examination results in context with the patient's clinical appearance as well as the exclusion of a broad variety of differential diagnoses.

The DelveInsight Urothelial Carcinoma market report gives the thorough understanding of urothelial carcinoma by including details, such as disease introduction, grading, histological features, staging system, classification, risk factors, pathogenesis, biomarkers, and diagnosis. It also provides treatment algorithms and treatment guidelines for urothelial carcinoma in the US, Europe, and Japan.

Urothelial Carcinoma Epidemiology

According to the American Cancer Society, in 2018 the expected new cases were about 81,190 of bladder cancer with 17,240 deaths. Even with optimal treatment, bladder cancer recurs in more than half of cases and may progress to muscle-invasive BC in up to 20% of these patients. The National Cancer Institute has also suggested a high increase in the number of cases of urothelial carcinoma with an estimated number of 80,470 newly diagnosed cases and 17,670 deaths in 2019.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of urothelial carcinoma in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and United Kingdom) and Japan from 2017 to 2028 for the following aspects:

• Diagnosed Incident Population of Urothelial Carcinoma

• Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma

• Severity-specific Diagnosed Incident Population of Urothelial Carcinoma

• Age-specific Diagnosed Incident Population of Urothelial Carcinoma

• Gender-specific Diagnosed Incident Population of Urothelial Carcinoma

• Tumor (T) stage-specific Diagnosed Incident Population of Urothelial Carcinoma

• Metastatic stage-specific Diagnosed Incident Population of Urothelial Carcinoma


There are several potential research papers and studies evaluated in order to analyze the overall epidemiology trend in the 7 Major Markets. Few are listed below:

According to a study conducted by Tanaka et al. titled “Diagnosis and Management of Urothelial Carcinoma of the Bladder”, stated that bladder carcinoma is the fourth most common cancer in men and the ninth most common cancer in women in the United States. It is also more common in men, with a male-to-female ratio of 3:1. Approximately 70,000 new cases of bladder carcinoma (52,000 in men and 18,000 in women) and approximately 14,000 deaths were expected in the United States in 2017. The study highlighted through evidence-based analysis that androgens might contribute to the increased incidence of UC of the bladder among men while some studies suggested that estrogens might exert a protective effect in women. In context of urothelial carcinoma subtypes, the natural history of non muscle-invasive disease recurrence is accounted as 50-90% depending on the stage and grade while progression to invasive cancer is accounted as 10-30%.

As per the study conducted by Kabaria et al. titled “Renal cell carcinoma: Links and Risks”, which stated that Kidney and renal pelvis cancer is among the top ten most common cancers in the world. The most frequent type of renal neoplasm is renal cell carcinoma (RCC), which accounts for nearly 85% of all renal malignancies. Urothelial carcinoma of the renal pelvis accounts for the remaining 10%. Also, worldwide, RCC is twice as common in males as females after adjusting for age with >50% of RCC is diagnosed among people aged 55-74 years.


Urothelial Carcinoma Drug Chapters

This segment of the Urothelial Carcinoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment of Urothelial Carcinoma, companies have shifted their focus toward the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Urothelial Carcinoma and awareness of the disease. The overall dynamics of Urothelial Carcinoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players, such as Eli Lilly and Company, UroGen Pharma, Astellas Pharma/Seattle Genetics, Incyte Corporation, Immunomedics, Nektar Therapeutics/Bristol-Myers Squibb, Rexahn Pharmaceuticals and Acerta Pharma will significantly increase the market during the forecast period (2019-2028).  


Urothelial Carcinoma Market Outlook

Urothelial Carcinoma (UC) encompass carcinomas of the bladder, ureters, and renal pelvis. Urothelial cancers make up the majority of cancers for bladder cancer. Urothelial carcinomas (UCs) are the fourth most commonly occurring tumors. Bladder tumors account for 90-95% of UCs and are the most common malignancy of the urinary tract.

Treatment for Urothelial Carcinoma (UC) can be employed in different classes of chemotherapy, immunotherapy, radiation therapy, target specific therapy, and surgical treatment. Chemotherapy majorly forms the first line of treatment mainly comprising platinum-based product wherein cisplatin-based chemotherapy is a chief product in the list of chemotherapeutics. The mainstay for treatment also comprises immunotherapy that helps the patient's own immune system to recognize and destroy cancer cells. Moreover, radiation therapy is often given along with chemotherapy to help the radiation work well. Transurethral Resection of Bladder Tumor (TURBT) is a gold standard surgical procedure for non-muscle invasive bladder cancer. Several post-chemotherapy surgeries are also performed with the rationale of degeneration of tumor at the initial disease sites.

This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Urothelial Carcinoma in 7MM is expected to change from 2019 to 2028.


Urothelial Carcinoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for urothelial carcinoma, such as Ramucirumab (Eli Lilly), UGN-101 (UroGen Pharma), Enfortumab vedotin (Astellas Pharma/Seattle Genetics), Pemigatinib (Incyte Corporation), Sacituzumab govitecan (Immunomedics), NKTR-214 (Nektar Therapeutics/Bristol-Myers Squibb), RX-3117 (Rexahn Pharmaceuticals), and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the urothelial carcinoma market.


Urothelial Carcinoma Report Insights

• Patient Population

• Therapeutic Approaches

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


Urothelial Carcinoma Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition


Urothelial Carcinoma Report Assessment

• Current Treatment Practices

• Unmet Needs

• Market Attractiveness

• Market Drivers and Barriers


Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Urothelial Carcinoma market

• Organize sales and marketing efforts by identifying the best opportunities for Urothelial Carcinoma market

• To understand the future market competition in the Urothelial Carcinoma market.

1. Key Insights

2. Urothelial Carcinoma Market Overview at a Glance

2.1. Market Share (%) Distribution of Urothelial Carcinoma in 2017

2.2. Market Share (%) Distribution of Urothelial Carcinoma in 2028

3. Disease Background and Overview: Urothelial Carcinoma (UC)

3.1. Introduction

3.2. Grading of Urothelial carcinoma

3.2.1. G1 tumors

               3.2.2. G3 tumors

     3.2.3. G2 tumors

3.3  Histological Features of Urothelial Neoplasm

3.3.2 Papillary urothelial neoplasm of low malignant potential (PUNLMP)

3.3.3 Low-grade papillary urothelial carcinoma

3.3.4 High-grade papillary urothelial carcinoma

3.4 TNM Staging System

3.4.1 Stages of urothelial carcinoma

3.5 Classification for Urothelial Carcinoma

3.5.1. Non-invasive inverted urothelial neoplasms

3.5.2. Urothelial dysplasia and carcinoma in situ with "early papillary formation"

3.5.3. Morphologic spectrum of inverted urothelial neoplasms

3.5.4. Invasive urothelial carcinoma

3.6 Risk factors for Urothelial Neoplasm

3.6.1 Cigarette smoke

3.6.2 Analgesics

3.6.3 Genetic effects

3.6.4 Occupational carcinogen exposure

3.7 Pathogenesis for Urothelial Neoplasm

3.8 Molecular pathogenesis and prognostics of bladder cancer for Urothelial carcinoma

3.8.1 The molecular basis of multifocality of urothelial tumors

3.8.2 Urothelial carcinoma phenotypes and their behavior

3.8.3 Molecular classification of urothelial carcinoma

3.8.4 Molecular classification of urothelial carcinoma

3.9 Biomarkers for Urothelial carcinoma

3.9.1 Proteomic and peptidomic analysis

3.9.2 Protein Biomarkers

3.9.3 Transcriptomic Biomarkers

3.9.4 Epigenetic DNA Methylation Markers

3.9.5 cfDNA, mutation, and microsatellite alterations

3.9.6 Urinary tumor RNA

3.9.7 Messenger RNAs (mRNAs) and Transfer RNA fragments (tRFs)

3.9.8 Extracellular vesicles (EVs) and exosomes

3.10 Diagnosis for Urothelial carcinoma

3.10.1 Aura Tek FDP Test

3.10.2 Cystoscopy and Cytology

3.10.3 BTA stat and BTA TRAK

3.10.4 NMP22 BC Test and NMP22 BladderChek Test

3.10.5 ImmunoCyt/uCyt

3.10.6 UroVysion

3.10.7 CertNDx

3.10.8 Cxbladder test

3.10.9 Cytologic-based tests

3.10.10 Urine cytology and FISH

             3.10.11 Imaging

             3.10.12 Photodynamic diagnosis (PDD)

3.10.13 Endoscopy

3.10.14 New upcoming technologies for diagnosis

3.10.15 Urothelial Carcinoma in Nutshell

4 Diagnostic Guidelines: American Urology Association (AUA)

4.1 Risk Stratification

4.1.1 Variant Histology

4.1.2 Urine marker after diagnosis of bladder cancer

4.1.3 TURBT/Repeat Resection: Timing, Technique, Goal, Indication

4.1.4 Intravesical Therapy; BCG/Maintenance; Chemotherapy/BCG Combinations

4.1.5 BCG Relapse and Salvage Regimen

5  Epidemiology and Patient Population

5.1 Key Findings

5.2 7MM Total Diagnosed Incident Patient Population of Urothelial Carcinoma

6 Country Wise-Epidemiology of Urothelial Carcinoma

6.1 United States

6.1.1 Assumptions and Rationale

6.1.2 Urothelial Carcinoma Diagnosed Incident Population in the United States

6.1.3 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United States

6.1.4 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United States

6.1.5 Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United States

6.1.6 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United States

6.1.7 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United States

6.1.8 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United States

6.2 EU5 Countries

6.2.1 Assumptions and Rationale

6.3 Germany

6.3.1 Diagnosed Incident Population in Germany

6.3.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Germany

6.3.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Germany

6.3.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Germany

6.3.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Germany

6.3.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Germany

6.3.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Germany

6.4 France

6.4.1 Urothelial Carcinoma Diagnosed Incident Population in France

6.4.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in France

6.4.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in France

6.4.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in France

6.4.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in France

6.4.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in France

6.4.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in France

6.5 Italy

6.5.1 Urothelial Carcinoma Diagnosed Incident Population in Italy

6.5.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Italy

6.5.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Italy

6.5.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Italy

6.5.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Italy

6.5.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Italy

6.5.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Italy

6.6 Spain

6.6.1 Urothelial Carcinoma Diagnosed Incident Population in Spain

6.6.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Spain

6.6.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Spain

6.6.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Spain

6.6.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Spain

6.6.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Spain

6.6.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Spain

6.7 United Kingdom

6.7.1 Urothelial Carcinoma Diagnosed Incident Population in the United Kingdom

6.7.2 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United Kingdom

6.7.3 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United Kingdom

6.7.4 Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United Kingdom

6.7.5 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United Kingdom

6.7.6 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United Kingdom

6.7.7 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United Kingdom

6.8 Japan

6.8.1 Assumptions and Rationale

6.8.2 Urothelial Carcinoma Diagnosed Incident Population in Japan

6.8.3 Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Japan

6.8.4 Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Japan

6.8.5 Urothelial Carcinoma Age-specific Diagnosed Incident Population in Japan

6.8.6 Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Japan

6.8.7 Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Japan

6.8.8 Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Japan

7 Treatment

7.1 Chemotherapy

7.1.1 Cisplatin-Based Regimens

7.1.2 Carboplatin-Based Regimens

7.1.3 Non-Platinum Regimens

7.1.4 Single-Agent Chemotherapy

7.2 Immunotherapy

7.2.1 Immunotherapy in the Platinum-Refractory Setting

7.3 Radiation Therapy

7.4 Targeting Growth Factor Receptor

7.5 Surgical Treatment

8 United States Guidelines: American Urological Association (AUA)

8.1.1 Intravesical Therapy; BCG/Maintenance; Chemotherapy/BCG Combinations

8.1.2 Risk-adjusted Surveillance and Follow-up Strategies

9 United States Guidelines: American Society of Clinical Oncology (ASCO) (2017)

9.1 Recommendations

9.1.1 Initial patient evaluation and counseling

9.2 Treatment

9.2.1 Neoadjuvant and adjuvant chemotherapy

9.2.2 Urinary diversion

9.2.3 Perioperative surgical management

9.2.4 Primary radiation therapy

10 European Guidelines: European Association of Urology (2018)

10.1 Recommendations

10.1.1 Kidney-sparing surgery

10.1.2 Percutaneous access

10.1.3 Segmental ureteral resection

10.1.4 Upper urinary tract instillation of topical agents

10.1.5 Radical nephroureterectomy

10.1.6 Lymph node dissection (LND)

10.1.7 Perioperative chemotherapy as an adjunct to radical nephroureterectomy

10.2 Follow-up

11 Japan Guidelines: Asia Consensus Statement on NCCN Clinical Practice Guideline for Bladder Cancer (2016)

12 Treatment Algorithm (NCCN Guidelines for United state: 2019)

13 Unmet Needs

14 Marketed Drugs

14.1 Keytruda: Merck

14.1.1 Product Description

14.1.2 Regulatory Milestones

14.1.3 Safety and Efficacy

14.1.4 Product Profile

14.2 Opdivo: Bristol-Myers Squibb

14.2.1 Product Description

14.2.2 Regulatory Milestones

14.2.3 Safety and Efficacy

14.2.4 Product Development Activities

14.2.5 Product Profile

14.3 Tecentriq: Genentech

14.3.1 Product Description

14.3.2 Regulatory Milestones

14.3.3 Safety and Efficacy

14.3.4 Product Development Activities

14.3.5 Product Profile

14.4 Bavencio: Merck

14.4.1 Product Description

14.4.2 Regulatory Milestones

14.4.3 Safety and Efficacy

14.4.4 Product Development Activities

14.4.5 Product Profile

14.5 Imfinzi: AstraZeneca

14.5.1 Product Description

14.5.2 Regulatory Milestones

14.5.3 Safety and Efficacy

14.5.4 Product Development Activities

14.5.5 Product Profile

14.6 Balversa: Janssen

14.6.1 Product Description

14.6.2 Regulatory Milestones

14.6.3 Safety and Efficacy

14.6.4 Product Development Activities

14.6.5 Product Profile

15 Emerging Drugs

15.1 Key Cross Competition

15.2 Ramucirumab: Eli Lilly and Company

15.2.1 Product Description

15.2.2 Clinical Development

15.2.3 Product Profile

15.3  UGN-101: UroGen Pharma

15.3.1 Product Description

15.3.2 Other Developmental Activities

15.3.3 Clinical Development

15.3.4 Product Profile

15.4 Enfortumab vedotin: Astellas Pharma/Seattle Genetics

15.3.5 Product Description

15.3.6 Other Developmental Activities

15.3.7 Clinical Development

15.3.8 Product Profile

15.5 Pemigatinib: Incyte Corporation

15.3.9 Product Description

15.3.10 Clinical Development

15.3.11 Product Profile

15.6 Sacituzumab govitecan (IMMU-132): Immunomedics

15.3.12 Product Description

15.3.13 Other Developmental Activities

15.3.14 Clinical Development

15.3.15 Product Profile

15.7 Bempegaldesleukin (NKTR-214): Nektar Therapeutics/Bristol-Myers Squibb

15.3.16 Product Description

15.3.17 Other Developmental Activities

15.3.18 Clinical Development

15.3.19 Product Profile

15.8 RX-3117: Rexahn Pharmaceuticals

15.3.20 Product Description

15.3.21 Other Developmental Activities

15.3.22 Clinical Development

15.3.23 Product Profile

15.9 ACP-196: Acerta Pharma

15.3.24 Product Description

15.3.25 Clinical Development

15.3.26 Product Profile

16 Urothelial Carcinoma: 7 Major Market Analysis

16.1 Key Findings

16.2 Market Size of Urothelial Carcinoma in 7MM

17 What Experts Say?

18 The United States Market Outlook

18.1 United States

18.1.1 Total Market size of Urothelial Carcinoma

18.1.2 Current Market Size by Therapies

18.1.3 Emerging Market Size by Therapies

19 EU-5 Countries: Market Outlook

19.1 Germany

19.1.1 Total Market size of Urothelial Carcinoma

19.1.2 Current Market Size by Therapies

19.1.3 Emerging Market Size by Therapies

19.2 France

19.2.1 Total Market size of Urothelial Carcinoma

19.2.2 Current Market Size by Therapies

19.2.3 Emerging Market Size by Therapies

19.3 Italy

19.3.1 Total Market size of Urothelial Carcinoma

19.3.2 Current Market Size by Therapies

19.3.3 Emerging Market Size by Therapies

19.4 Spain

19.4.1 Total Market size of Urothelial Carcinoma

19.4.2 Current Market Size by Therapies

19.4.3 Emerging Market Size by Therapies

19.5 United Kingdom

19.5.1 Total Market size of Urothelial Carcinoma

19.5.2 Current Market Size by Therapies

19.5.3 Emerging Market Size by Therapies

20 Japan: Market Outlook

20.1 Japan Market Size

20.1.1 Total Market size of Urothelial Carcinoma

20.1.2 Current Market Size by Therapies

20.1.3 Emerging Market Size by Therapies

21 Market Drivers

22 Market Barriers

23 Appendix

24 Report Methodology

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight

Table 1: Histological features of papillary urothelial lesions

Table 2: TNM staging system

Table 3: Sub-grouping of the non-invasive urothelial neoplasms with an inverted growth pattern

Table 4: FDA-approved urinary biomarkers for the detection of bladder cancer

Table 5: Performance of Markers in Surveillance Setting from Pooled Analyses

Table 6: AUA Nomenclature Linking Statement Type to Level of Certainty, Magnitude of Benefit or Risk/Burden, and Body of Evidence Strength

Table 7: Staging of primary tumors (T) in bladder cancer

Table 8: 2004 World Health Organization/International Society of Urologic Pathologists: Classification of Non-muscle Invasive Urothelial Neoplasia

Table 9: AUA Risk Stratification for Non-Muscle Invasive Bladder Cancer

Table 10: Urothelial Carcinoma Total Diagnosed Incident Population in the 7MM (2017-2028)

Table 11: Urothelial Carcinoma Diagnosed Incident Population in the United States (2017-2028)

Table 12: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United States (2017-2028)

Table 13: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United States (2017-2028)

Table 14: Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United States (2017-2028)

Table 15: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United States (2017-2028)

Table 16: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United States (2017-2028)

Table 17: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United States (2017-2028)

Table 18: Urothelial Carcinoma Diagnosed Incident Population in Germany (2017-2028)

Table 19: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Germany (2017-2028)

Table 20: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Germany (2017-2028)

Table 21: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Germany (2017-2028)

Table 22: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Germany (2017-2028)

Table 23: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Germany (2017-2028)

Table 24: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Germany (2017-2028)

Table 25: Urothelial Carcinoma Diagnosed Incident Population in France (2017-2028)

Table 26: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in France (2017-2028)

Table 27: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in France (2017-2028)

Table 28: Urothelial Carcinoma Age-specific Diagnosed Incident Population in France (2017-2028)

Table 29: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in France (2017-2028)

Table 30: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in France (2017-2028)

Table 31: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in France (2017-2028)

Table 32: Urothelial Carcinoma Diagnosed Incident Population in Italy (2017-2028)

Table 33: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Italy (2017-2028)

Table 34: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Italy (2017-2028)

Table 35: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Italy (2017-2028)

Table 36: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Italy (2017-2028)

Table 37: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Italy (2017-2028)

Table 38: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Italy (2017-2028)

Table 39: Urothelial Carcinoma Diagnosed Incident Population in Spain (2017-2028)

Table 40: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Spain (2017-2028)

Table 41: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Spain (2017-2028)

Table 42: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Spain (2017-2028)

Table 43: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Spain (2017-2028)

Table 44: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Spain (2017-2028)

Table 45: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Spain (2017-2028)

Table 46: Urothelial Carcinoma Diagnosed Incident Population in the United Kingdom (2017-2028)

Table 47: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United Kingdom (2017-2028)

Table 48: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United Kingdom (2017-2028)

Table 49: Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United Kingdom (2017-2028)

Table 50: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United Kingdom (2017-2028)

Table 51: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United Kingdom (2017-2028)

Table 52: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United Kingdom (2017-2028)

Table 53: Urothelial Carcinoma Diagnosed Incident Population in Japan (2017-2028)

Table 54: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Japan (2017-2028)

Table 55: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Japan (2017-2028)

Table 56: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Japan (2017-2028)

Table 57: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Japan (2017-2028)

Table 58: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Japan (2017-2028)

Table 59: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Japan (2017-2028)

Table 60: Treatment options for metastatic urothelial carcinoma

Table 61: Guidelines for kidney-sparing management of upper urinary tract urothelial cell carcinoma

Table 62: Summary of evidence and guidelines for radical nephroureterectomy

Table 63: Summary for the follow-up of UTUC

Table 64: Summary of evidence and recommendations for the treatment of localized renal cell cancer

Table 65: Summary of evidence and recommendations for radical and partial nephrectomy techniques

Table 66: Asia Consensus Statement (ACS) on the NCCN Guideline for bladder cancer version

Table 67: Comparison of Emerging Drugs Under Development

Table 68: Ramucirumab, Clinical Trial Description

Table 69: UGN-101, Clinical Trial Description

Table 70: Enfortumab vedotin, Clinical Trial Description

Table 71: Pemigatinib, Clinical Trial Description

Table 72: Sacituzumab govitecan, Clinical Trial Description

Table 73: NKTR-214, Clinical Trial Description

Table 74: NKTR-214, Clinical Trial Description

Table 75: Clinical Trial Description

Table 76: 7 Major Market Size of Urothelial Carcinoma in USD Million (2017-2028)

Table 77: United States Market Size of Urothelial Carcinoma, USD Million (2017-2028)

Table 78: Market size of Urothelial Carcinoma by therapies in United States, in USD Million (2017-2028)

Table 79: Market size of Urothelial Carcinoma by therapies in United States, in USD Million (2017-2028)

Table 80: Germany Market Size of Urothelial Carcinoma, USD Million (2017-2028)

Table 81: Market size of Urothelial Carcinoma by therapies in Germany, in USD Million (2017-2028)

Table 82: Market size of Urothelial Carcinoma by therapies in Germany, in USD Million (2017-2028)

Table 83: France Market Size of Urothelial Carcinoma, USD Million (2017-2028)

Table 84: Market size of Urothelial Carcinoma by therapies in France, in USD Million (2017-2028)

Table 85: Market size of Urothelial Carcinoma by therapies in France, in USD Million (2017-2028)

Table 86: Italy Market Size of Urothelial Carcinoma, USD Million (2017-2028)

Table 87: Market size of Urothelial Carcinoma by therapies in Italy, in USD Million (2017-2028)

Table 88: Market size of Urothelial Carcinoma by therapies in Italy, in USD Million (2017-2028)

Table 89: Spain Market Size of Urothelial Carcinoma, USD Million (2017-2028)

Table 90: Market size of Urothelial Carcinoma by therapies in Spain, in USD Million (2017-2028)

Table 91: Market size of Urothelial Carcinoma by therapies in Spain, in USD Million (2017-2028)

Table 92: United Kingdom Market Size of Urothelial Carcinoma, USD Million (2017-2028)

Table 93: Market size of Urothelial Carcinoma by therapies in the United Kingdom, in USD Million (2017-2028)

Table 94: Market size of Urothelial Carcinoma by therapies in the United Kingdom, in USD Million (2017-2028)

Table 95: Japan Market Size of Urothelial Carcinoma, USD Million (2017-2028)

Table 96: Market size of Urothelial Carcinoma by therapies in Japan, in USD Million (2017-2028)

Table 97: Market size of Urothelial Carcinoma by therapies in Japan, in USD Million (2017-2028)

Figure 1: Histological grading of papillary urothelial neoplasms. (a) Benign urothelial papilloma; (b) papillary urothelial neoplasm of low malignant potential; (c) low-grade papillary urothelial carcinoma; and (d) high-grade papillary urothelial carcinoma.

Figure 2: Schematic representation of the two major pathways of urothelial carcinogenesis: Note that

Figure 3: Molecular Biology of bladder cancer

Figure 4: Monitoring of Biomarkers

Figure 5: Urothelial Carcinoma Total Diagnosed Incident Patient Population in the 7MM (2017-2028)

Figure 6: Urothelial Carcinoma Diagnosed Incident Population in the United States (2017-2028)

Figure 7: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United States (2017-2028)

Figure 8: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United States (2017-2028)

Figure 9: Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United States (2017-2028)

Figure 10: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United States (2017-2028)

Figure 11: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United States (2017-2028)

Figure 12: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United States (2017-2028)

Figure 13: Urothelial Carcinoma Diagnosed Incident Population in Germany (2017-2028)

Figure 14: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Germany (2017-2028)

Figure 15: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Germany (2017-2028)

Figure 16: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Germany (2017-2028)

Figure 17: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Germany (2017-2028)

Figure 18: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Germany (2017-2028)

Figure 19: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Germany (2017-2028)

Figure 20: Urothelial Carcinoma Diagnosed Incident Population in France (2017-2028)

Figure 21: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in France (2017-2028)

Figure 22: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in France (2017-2028)

Figure 23: Urothelial Carcinoma Age-specific Diagnosed Incident Population in France (2017-2028)

Figure 24: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in France (2017-2028)

Figure 25: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in France (2017-2028)

Figure 26: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in France (2017-2028)

Figure 27: Urothelial Carcinoma Diagnosed Incident Population in Italy (2017-2028)

Figure 28: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Italy (2017-2028)

Figure 29: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Italy (2017-2028)

Figure 30: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Italy (2017-2028)

Figure 31: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Italy (2017-2028)

Figure 32: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Italy (2017-2028)

Figure 33: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Italy (2017-2028)

Figure 34: Urothelial Carcinoma Diagnosed Incident Population in Spain (2017-2028)

Figure 35: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Spain (2017-2028)

Figure 36: Urothelial Carcinoma Severity-specific Diagnosed Incident Population of in Spain (2017-2028)

Figure 37: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Spain (2017-2028)

Figure 38: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Spain (2017-2028)

Figure 39: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Spain (2017-2028)

Figure 40: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Spain (2017-2028)

Figure 41: Urothelial Carcinoma Diagnosed Incident Population in the United Kingdom (2017-2028)

Figure 42: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in the United Kingdom (2017-2028)

Figure 43: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in the United Kingdom (2017-2028)

Figure 44: Urothelial Carcinoma Age-specific Diagnosed Incident Population in the United Kingdom (2017-2028)

Figure 45: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in the United Kingdom (2017-2028)

Figure 46: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in the United Kingdom (2017-2028)

Figure 47: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in the United Kingdom (2017-2028)

Figure 48: Urothelial Carcinoma Diagnosed Incident Population in Japan (2017-2028)

Figure 49: Total Cases of Locally Advanced/Metastatic Urothelial Carcinoma in Japan (2017-2028)

Figure 50: Urothelial Carcinoma Severity-specific Diagnosed Incident Population in Japan (2017-2028)

Figure 51: Urothelial Carcinoma Age-specific Diagnosed Incident Population in Japan (2017-2028)

Figure 52: Urothelial Carcinoma Gender-specific Diagnosed Incident Population in Japan (2017-2028)

Figure 53: Urothelial Carcinoma Tumor (T) stage-specific Diagnosed Incident Population in Japan (2017-2028)

Figure 54: Urothelial Carcinoma Metastatic stage-specific Diagnosed Incident Population in Japan (2017-2028)

Figure 55: Proposed algorithm for the management of Muscle invasive urothelial cancer

Figure 56: Proposed algorithm for management of metastatic urothelial carcinoma based on ESMO guidelines

Figure 57: Mechanisms of BCG immunotherapy and its outlook for bladder cancer

Figure 58: Frequency of FGFR aberrations

Figure 59: Symptoms: Proposed flowchart for the management of upper urinary tract urothelial cell carcinoma

Figure 60: Unmet Needs of Urothelial Carcinoma

Figure 61: 7 Major Market Size of Urothelial Carcinoma in USD Million (2017-2028)

Figure 62: Market Size of Urothelial Carcinoma in the United States, USD Millions (2017-2028)

Figure 63: Market size of Urothelial Carcinoma by therapies in the US, in USD Million (2017-2028)

Figure 64: Market size of Urothelial Carcinoma by therapies in the US, in USD Million (2017-2028)

Figure 65: Market Size of Urothelial Carcinoma in Germany, USD Millions (2017-2028)

Figure 66: Market size of Urothelial Carcinoma by therapies in Germany, in USD Million (2017-2028)

Figure 67: Market size of Urothelial Carcinoma by therapies in Germany, in USD Million (2017-2028)

Figure 68: Market Size of Urothelial Carcinoma in France, USD Millions (2017-2028)

Figure 69: Market size of Urothelial Carcinoma by therapies in France, in USD Million (2017-2028)

Figure 70: Market size of Urothelial Carcinoma by therapies in France, in USD Million (2017-2028)

Figure 71: Market Size of Urothelial Carcinoma in Italy, USD Millions (2017-2028)

Figure 72: Market size of Urothelial Carcinoma by therapies in Italy, in USD Million (2017-2028)

Figure 73: Market size of Urothelial Carcinoma by therapies in Italy, in USD Million (2017-2028)

Figure 74: Market Size of Urothelial Carcinoma in Spain, USD Millions (2017-2028)

Figure 75: Market size of Urothelial Carcinoma by therapies in Spain, in USD Million (2017-2028)

Figure 76: Market size of Urothelial Carcinoma by therapies in Spain, in USD Million (2017-2028)

Figure 77: Market Size of Urothelial Carcinoma in the United Kingdom, USD Millions (2017-2028)

Figure 78: Market size of Urothelial Carcinoma by therapies in the United Kingdom, in USD Million (2017-2028)

Figure 79: Market size of Urothelial Carcinoma by therapies in the United Kingdom, in USD Million (2017-2028)

Figure 80: Market Size of Urothelial Carcinoma in Japan, USD Millions (2017-2028)

Figure 81: Market size of Urothelial Carcinoma by therapies in Japan, in USD Million (2017-2028)

Figure 82: Market size of Urothelial Carcinoma by therapies in Japan, in USD Million (2017-2028)

Figure 83: Market Drivers

Figure 84: Market Barriers

  • Tags:
  • Urothelial Carcinoma market
  • Urothelial Carcinoma market researc...
  • Urothelial Carcinoma market insight
  • Urothelial Carcinoma market trends
  • Urothelial Carcinoma market forecas...
  • Urothelial Carcinoma market share
  • Urothelial Carcinoma pipeline drugs
  • Urothelial Carcinoma treatment algo...
  • Urothelial Carcinoma drugs
  • Urothelial Carcinoma sales forecast...
  • Urothelial Carcinoma market size
  • Urothelial Carcinoma disease
  • Urothelial Carcinoma epidemiology
  • Urothelial Carcinoma
  • Urothelial Carcinoma Companies
  • Urothelial Carcinoma Pipeline

Forward to Friend

Need A Quote